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Abstract Neuropsychiatric systemic lupus erythematosus
(NPSLE) is a generic definition referring to a series of
neurological and psychiatric symptoms directly related to
systemic lupus erythematosus (SLE). NPSLE includes
heterogeneous and rare neuropsychiatric (NP) manifesta-
tions involving both the central and peripheral nervous
system. Due to the lack of a gold standard, the attribution of
NP symptoms to SLE represents a clinical challenge that
obligates the strict exclusion of any other potential cause. In
the acute setting, management of these patients does not
differ from other non-SLE subjects presenting with the same
NP manifestation. Afterwards, an individualized therapeutic
strategy, depending on the presenting manifestation and
severity of symptoms, must be started. Clinical trials in
NPSLE are scarce and most of the data are extracted from
case series and case reports. High-dose glucocorticoids and
intravenous cyclophosphamide remain the cornerstone for
patients with severe symptoms that are thought to reflect
inflammation or an underlying autoimmune process. Ritux-
imab, intravenous immunoglobulins, or plasmapheresis may
be used if response is not achieved. When patients present
with mild to moderate NP manifestations, or when mainte-
nance therapy is warranted, azathioprine and mycophenolate
may be considered. When symptoms are thought to reflect a
thrombotic underlying process, anticoagulation and anti-
platelet agents are the mainstay of therapy, especially if
antiphospholipid antibodies or antiphospholipid syndrome
are present. Recent trials on SLE using new biologicals,
based on newly understood SLE mechanisms, have shown
promising results. Based on what we currently know about
its pathogenesis, it is tempting to speculate how these new
therapies may affect the management of NPSLE patients.
This article provides a comprehensive and critical review of
the literature on the epidemiology, pathophysiology, diag-
nosis, and management of NPSLE. We describe the most
common pharmacological treatments used in NPSLE, based
on both a literature search and our expert opinion. The
extent to which new drugs in the advanced development of
SLE, or the blockade of new targets, may impact future
treatment of NPSLE will also be discussed.
Key Points
A strict differential diagnosis and individualization
of treatment, depending on the neuropsychiatric
presentation and severity of symptoms, are crucial in
neuropsychiatric systemic lupus erythematosus
(NPSLE).
In clinical practice, therapies are directed to a
presumptive pathophysiologic process
(inflammatory, thrombotic, or both).
New biological drugs against different novel targets
are currently being studied in systemic lupus
erythematosus (SLE). Some of these targets are
thought to contribute to NPSLE pathogenesis and
may offer potential therapeutic options.
Increased understanding of the pathogenesis of
NPSLE may lead to the development of novel
immunomodulatory therapies that may replace the
current therapies.
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1 Introduction
Systemic lupus erythematosus (SLE) is a chronic multi-
system inflammatory autoimmune disease with a waxing
and waning course and a broad spectrum of clinical pre-
sentations [1]. The involvement of the nervous system in
SLE patients leads to a nonspecific and heterogeneous
group of neuropsychiatric (NP) manifestations [2]. A major
issue in clinical evaluation is the attribution of NP symp-
toms to SLE. No laboratory or radiological biomarker nor
other formal system exists for establishing a diagnosis and
guiding therapy decisions in neuropsychiatric SLE
(NPSLE). In clinical practice, an individual multidisci-
plinary diagnostic and therapeutic approach based on the
suspected cause and severity of symptoms is recommended
[3].
To date, only one randomized controlled treatment trial
in NPSLE has been undertaken. In addition to the scarcity
of trials, several therapeutic strategies report benefits in
different aspects of NPSLE management: primary pre-
vention, resolution and stabilization of acute symptoms,
maintenance therapy, and secondary prevention.
We provide a comprehensive and critical review of the
literature on the epidemiology, classification, pathophysi-
ology, and diagnostic approach of NPSLE, and discuss the
current pharmacological armamentarium and potential
future therapies to treat patients with NPSLE.
2 Epidemiology
Epidemiological studies have suggested differences in the
prevalence of SLE and NPSLE according to age, sex, and
ethnicity. It is well-established that SLE is substantially
increased in females of child-bearing age (female:male
ratio is 8–15:1) [4]. Although a greater incidence of neu-
rological involvement in females and an increased risk of
seizures in males have been reported, there is limited evi-
dence to support an association between gender and
NPSLE since most of the studies do not provide correction
for important confounders such as comorbidities [5–7]. NP
manifestations are more frequently seen in African
descendants, Hispanics, and Asians than in White indi-
viduals;[8–10] however, NP damage occurs more fre-
quently among White patients, as described in the
LUMINA and Maryland cohorts [11, 12].
NP manifestations usually occur early in the course of
SLE, and in 39–50 % of patients it is the presenting
symptom of SLE [13]. An important variability in NPSLE
prevalence (range 4–91 %), incidence (range 8–40 %), and
frequency of specific NPSLE events has been reported [13–
15]. Unterman et al. reported a meta-analysis pooling all
available studies, resulting in a population of 5057 SLE
patients. The prevalence of NPSLE was 44.5 % in
prospective studies versus 17.6 % in retrospective studies
[16]. Disparities in frequency have been mainly attributed
to differences within the definition used and stringency in
attributing the events to SLE. Most of these studies
included minor, nonspecific symptoms (e.g. mild depres-
sion or anxiety) that, to some degree, are known to be
investigator-dependent [17]. After exclusion of these minor
events and peripheral nervous system (PNS) syndromes,
Kampylafka et al. reported an NPSLE prevalence of 4.3 %
and an incidence rate of 7.8/100 person years [15]. Sub-
sequently, the proportion of major central nervous system
(CNS) increased significantly when compared with data
reported previously (i.e. myelopathy with a prevalence of
22 % instead of 1–1.5 %) [14, 15].
NPSLE is a severe complication of SLE that contributes
considerably to quality of life, morbidity and mortality. NP
events are associated with a lower quality of life over time,
with poor prognosis in SLE patients [18]. We recently
reported a tenfold increase in mortality rate in NPSLE
compared with the general population [19].
3 Classification of Neuropsychiatric Systemic
Lupus Erythematosus (NPSLE)
In 1999, the American College of Rheumatology (ACR)
published a set of NPSLE case definitions, including 12
CNS and 7 PNS manifestations. The CNS manifestations
can be divided into four psychiatric syndromes and eight
neurological syndromes, and were also divided into focal
(events presenting as focal neurologic deficits) and diffuse
(including cognitive disorder, mood disorder, psychosis,
acute confusional state, and anxiety disorder) (Table 1)
[20]. Although this standardized approach to categorize NP
events in SLE patients has improved the description and
classification of NPSLE in clinical studies, its usefulness in
clinical practice is limited. Several CNS syndromes
(headache, anxiety, mood disorder, and mild cognitive
disorder) included in these definitions are nonspecific.
Although frequently seen in SLE patients, these syndromes
may only be attributed to an SLE in selected cases within
an appropriate clinical context [21, 22]. Other CNS mani-
festations not included in the ACR definitions, such as
neuromyelitis optica or posterior reversible encephalopathy
syndrome, have been increasingly recognized to be linked
to SLE [23, 24].
In a clinical setting, NPSLE can also be classified
according to the suspected underlying pathophysiologic
process. Two different pathophysiologic processes are
recognized to contribute to NP symptoms in NPSLE: (1)
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inflammatory, related to a pro-inflammatory and/or
autoimmune-mediated cause; and (2) thrombotic/ischemic,
associated with vascular occlusion, microangiopathy, and
hemorrhage (see below). In a considerable proportion of
NPSLE patients, both pathophysiologic changes have been
reported to coexist and to manifest as a wide heterogeneous
group of NP features. Both ischemic and inflammatory
NPSLE have been included in the term primary NPSLE. In
addition, secondary NPSLE refers to SLE patients whose
NP symptoms are due to the medication for SLE or to SLE-
related organ damage [3].
4 Pathogenesis
SLE is characterized by the loss of tolerance to nuclear
antigens, the formation of autoantibodies, and immune
complexes, resulting in complement activation, cell
destruction and tissue inflammation. Prominent features are
alterations in B- and T-cell activation, aberrant clearance of
apoptotic material, and an activated type I interferon (IFN)
system [1]. The pathogenic processes that lead to damage
or dysfunction in the nervous system of SLE patients, and
results in pathophysiological changes and ultimately in
clinical manifestations, remains poorly understood.
Dozens of risk factors indicative of putative mechanisms
have been proposed as candidates in the genesis of nervous
system involvement in SLE (Table 2) [2, 25]. Two separate
main pathogenic mechanisms are hypothesized to lead to
NPSLE [3, 26].
1. Autoimmune or inflammation characterized by brain
dysfunction due to autoantibodies or inflammatory
mediators with either a disrupted blood–brain barrier
(BBB) or intrathecal formation of immune complexes
and the presence of inflammatory mediators. Neuronal
dysfunction may be induced directly by these
mediators or indirectly through activation of other
neural cells.
2. Vascular injury and occlusion characterized by a
thrombotic process of the large and small (microan-
giopathy) intracranial vessels due to autoantibody-
mediated vascular injury, immune complexes, com-
plement deposition, leukoagglutination, and acceler-
ated atherosclerosis.
Several genetic studies implicate the possible role of
mutations in TREX1, a gene encoding the three-prime
repair exonuclease 1 (DNase III), in NPSLE [27]. Poly-
morphisms in this gene have been associated with neuro-
logical involvement in European SLE patients, especially
with seizures [28]. Loss-of-function mutations in TREX1
have been shown to augment production of type I IFNs in
mice and also in a patient with early-onset cerebral NPSLE
[29, 30]. Furthermore, the HLA-DRB1*04 and
rs10181656(G) alleles have been associated with ischemic
cardiovascular disease (CVD) in White SLE patients,
independent of the cardiovascular traditional risk factors
and anticardiolipin antibody (aCL) status [31, 32].
Autoantibodies are thought to play a crucial role in the
NPSLE pathogenesis. Brain tissue-reactive antibodies in
NPSLE can be synthesized in the CNS or in peripheral
organs (lymph nodes and bone marrow). In the latter, these
autoantibodies must pass through the BBB of SLE patients
to exert an effect upon neurons. Why and how the integrity
of the BBB is compromised is not fully understood. The
majority of studies simply report the higher presence of a
certain antibody in serum and/or cerebrospinal fluid (CSF)
of NPSLE patients, and none of these findings have
remained as reproducible as to become a specific bio-
marker for NPSLE or any individual NP manifestation.
Although no specific autoantibodies have been identified,
several studies have confirmed an important association
between antiphospholipid antibodies (aPL), especially
Table 1 Neuropsychiatric
syndromes according to the
American College of
Rheumatology [20]
Central nervous system Peripheral nervous system
Neurological syndromes Focal 1. Aseptic meningitis 13. Guillain-Barre´
2. Cerebrovascular disease 14. Autonomic disorder
3. Demyelinating syndrome 15. Mononeuropathy (single/multiplex)
4. Headache 16. Myasthenia gravis
5. Movement disorder 17. Cranial neuropathy
6. Myelopathy 18. Plexopathy
7. Seizure disorders 19. Polyneuropathy
Psychiatric syndromes Diffuse 8. Acute confusional state
9. Anxiety disorder
10. Cognitive dysfunction
11. Mood disorder
12. Psychosis
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lupus anticoagulant (LAC), and antiribosomal P antibodies,
and cerebrovascular disease and psychosis, respectively
[33].
There is also evidence that accelerated atherosclerotic
disease occurring in SLE patients can lead to early cere-
brovascular disease. Factors contributing to premature
atherosclerotic vascular disease include traditional factors
such as smoking, dyslipidemia, increasing age, obesity,
hypertension, and longer disease duration, in addition to
other factors such as homocysteinemia, higher damage
score, duration and cumulative doses of corticosteroids,
and low levels of vitamin D [34–37].
A substantial need exists for developing and validating a
range of laboratory and radiological biomarkers to reliably
capture all the different aspects of NPSLE heterogeneity
and to further improve its prevention, diagnosis, and
therapy.
5 Diagnostic Approach in NPSLE
In SLE,\40 % of the NP symptoms will be attributed to
SLE-induced nervous system damage. In the remaining
cases, other causes (i.e. therapy, primary NP disorders) will
better explain these symptoms. Given the absence of a gold
standard in the diagnostic approach, NPSLE remains a
diagnosis per exclusionem and is mainly based on expert
opinion. In all patients, there is an obligation to first
exclude other causes such as infection, coincidental disease
processes, metabolic abnormalities, or drug side effects. In
SLE patients presenting with unexplained NP symptoms or
signs suggestive of NP disease, the first step would be to
evaluate and characterize the NP symptoms, similarly to
patients without SLE [38]. Neurological assessment should
be focused on headache, signs of seizures, alertness, and
motor and sensory deficits, while psychiatric evaluation
Table 2 Suggested
pathogenetic factors in
neuropsychiatric systemic lupus
erythematosus
Genetic
TREX1 gene
HLA-DRB1*04
STAT4 rs10181656
Autoantibodies
Brain cells and constituents: neuronal, brain reactive, gangliosides, neurofilament
(a-internexin), antibrain synaptosomal, anti-GFAP, anti-UCH-L1
Brain neurotransmitters: anti-NMDA/NR2, GABA-B
aCL/LAC/b2-glycoprotein I
Sm/Ro (SSA)/U1 RNP/ribosomal proteins/histone
Endothelial cells
Other: MAP2, serum lymphocytotoxic antibodies, triosephosphate isomerase,
Hsp70, a-tubulin, peroxiredoxin 4, splicing factor, SFRS3, Nedd5
Cytokines
Interleukins: IL-1, IL-2, IL-6, IL-8, IL-10, TNF, APRIL, IFN-a, IFN-c
Chemokines: CCL5, CCL2 (monocyte chemotactic protein 1), CXCL10 (IP-10)
Accelerated atherosclerosis
Traditional risk factors
Inflammatory risk factors
SLE-related risk factors (aCL and LAC, lupus nephritis, prednisone, low vitamin D)
Other SLE-specific factors
SLE disease activity/duration
Heart valve disease
Immune complexes
Complement deposition
Others
PAI-1
aCL anticardiolipin antibodies, APRIL a proliferation-inducing ligand, CCL chemokine ligand,
CXCL C-X-C motif chemokine, IL interleukin, IFN interferon, GABA-B c-aminobutyric acid type
B receptors, GFAP glial fibrillary acid protein, HLA human leukocyte antigen, IP interferon c-
induced protein, LAC lupus anticoagulant, MAP2 microtubule-associated protein 2, NMDA/NR2
N-methyl-D-aspartate receptor, PAI plasminogen activator inhibitor, RNP ribonucleoprotein, SSA
Sjo¨gren’s syndrome-related antigen A, SLE systemic lupus erythematosus, TNF tumor necrosis
factor, UCH-L1 ubiquitin carboxyl-terminal hydrolase isozyme L1
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should assess behavior, cognition, perception, and thinking,
as well as mood and affect. Formal neuropsychological
testing must be carried out when there is a clinical suspi-
cion of impaired cognitive ability. General SLE activity
must be assessed by a rheumatologist, which may con-
tribute to the attribution of NP events to SLE, especially
diffuse manifestations. Symptoms of atherosclerotic dis-
ease, thrombotic events, and cardiovascular risk factors
should be assessed [3, 26].
The diagnostic work-up of these patients should con-
sider all investigations that should be carried out in non-
SLE patients presenting with the same manifestations [26,
38]. In clinical practice, NPSLE diagnosis is achieved case-
by-case using different clinical, laboratory, electrophysio-
logical, and neuroimaging data, depending on the clinical
presentation (Table 3). Among all circulating autoanti-
bodies, aPL, including aCL, LAC, and b2-glycoprotein
antibodies, provide the greatest diagnostic information in
NPSLE, especially in patients with focal NP events such as
cerebrovascular disease and seizures [39]. It has been
suggested serum antiribosomal P antibodies are specifically
related to lupus psychosis. An association between NPSLE
and anti-NMDA (N-methyl-D-aspartate antibodies) has also
been suggested but studies are contradictory and its pres-
ence is not associated with a specific NPSLE syndrome
[33]. Autoantibodies to aquaporin 4 can help in the diag-
nostic process of a patient presenting with myelopathy and
optic neuritis [23]. The measurement of autoantibodies or
cytokines in CSF is not recommended in clinical practice at
this time due to the lack of specificity [26].
Magnetic resonance imaging (MRI) is the neuroimaging
technique of choice in NPSLE and remains the neu-
roimaging test used in clinical practice. This technique is
able to localize abnormalities in the brain and spine,
allowing the identification of lesions associated with NPSLE
(e.g. infarcts or myelopathy) and many differential disorders
(e.g. tumors or infections). However, MRI is nonspecific and
in a significant number of patients no abnormalities or only
aspecific white matter hyperintensities are found, indepen-
dent of the NPSLE syndrome and severity [40].
Advanced neuroimaging methods based on MRI (dif-
fusion-weighted imaging, proton magnetic resonance
spectroscopy, and magnetic transfer imaging) and nuclear
imaging testing (positron emission tomography and sin-
gle photon emission computed tomography) have been
proposed to be useful in the identification of NP
involvement in SLE patients; however, the clinical rele-
vance of these tests in individual patients requires further
evidence and validation. Since no single imaging test
covers all the different mechanisms leading to brain
injury occurring in these patients, multimodal imaging
has been proposed as a future potential standard of
practice in NPSLE [41].
Electrophysiological studies are used when seizures and
neuropathies are suspected clinically. These tests will help
in the diagnostic process of the neurological syndrome;
however, there are no specific signs for NPSLE. Elec-
troencephalography alterations may be somehow useful in
guiding therapy. Focal epileptiform discharges would be
more suggestive of an ischemic nidus compared with dif-
fuse disorganized activity, which is more suggestive of
inflammation. Typical epileptiform patterns are present in
less than half of the SLE patients with seizure, which may
be predictive of seizure recurrence [42, 43]. Florica et al.
described the electrophysiological abnormalities in a large
SLE cohort. In total, 8 % of these patients had a neu-
ropathy associated with SLE. Axonal neuropathy was seen
in 70 % of patients, and signs of demyelination was seen in
20 % of patients [44].
Due to the lack of specificity of all the tests used in the
diagnostic process, the attribution of NP to SLE remains a
challenge. Bortoluzzi et al. proposed an algorithm that may
assist the rheumatologist in the attribution of NP events to
SLE [45]. We have previously recommended multidisci-
plinary expert consensus after a standardized assessment as
the best strategy for diagnosing and classifying NPSLE. In
some cases, the diagnosis will be inevitably presumptive;
therefore, patients must be prospectively followed and
reanalyzed to avoid misclassification [3].
6 Therapeutic Strategies
Once other potential causes are ruled out and NP symptoms
of the patient are attributed to SLE, an individualized
therapeutic strategy, depending on the presenting mani-
festation and severity, should be started. In 2010, the
European League Against Rheumatism (EULAR) pub-
lished a series of recommendations for the management of
NPSLE. The management of these patients always includes
a general therapeutic approach that does not differ from
other non-SLE individuals presenting with the same NP
manifestation. Correction of aggravating factors, nonphar-
macological interventions, and symptomatic therapy when
appropriate may initially be considered as general treat-
ment [38].
The potential role of some therapies (e.g. hydroxy-
chloroquine) in the primary prevention of major NPSLE,
especially cerebrovascular disease, has also been suggested
[46].
Specific NPSLE therapy remains relatively empirical
due to the scarcity of controlled trials. In clinical practice,
depending on the suspected underlying pathophysiological
process, therapy will be directed at inflammation or at
prevention of ischemic events [3]. Manifestations that are
thought to reflect an immune-inflammatory state or, in the
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Table 3 Diagnostic approach in NPSLE
All patients Measure disease activity
Therapy history SLE-specific therapy/psychoactive drugs
Laboratory tests aCL and LAC/complement/urine sediment/exclude metabolic abnormalities/
autoantibody profiling
Aseptic meningitis LP Exclude infection
MRI Exclude infection/exclude subarachnoid hemorrhage
Additional laboratory tests Serology testing for infectious diseases/cultures
Cerebrovascular
disease (TIA/stroke)
MRI Evaluation infarcts
Echocardiogram
Doppler ultrasonography of
the carotid arteries
MRA and LP If suspicion of cerebral vasculitis
Demyelinating
syndrome
MRI Exclude infection/exclude malignancy/signs of MS
LP Exclude infection/oligoclonal bands
Additional laboratory tests Vitamin B12/serology testing for infectious diseases
Headache (if chronic
and recalcitrant)
MRI Exclude infection/exclude infarction/exclude malignancy/exclude PRES
LP Exclude infection and cranial hypertension
Movement disorder MRI Exclude stroke/exclude infection/exclude malignancy
Additional laboratory tests Copper (Wilson disease)
Myelopathy MRI Exclude infection/exclude malignancy/signs of MS/signs of optic neuritis
MRI–spine Exclude infection/exclude malignancy/exclude AVM/confirm LETM
LP Exclude infection/oligoclonal bands
Additional laboratory tests Serology testing for infectious diseases/anti-NMO antibodies
Seizure MRI Exclude infection/exclude malignancy
EEG Confirm seizure
LP Exclude infection
Additional laboratory tests Serology testing for infectious diseases
Acute confusional state MRI Exclude infection/exclude malignancy/exclude other neurological diseases
LP Exclude infection
Additional laboratory tests Serology testing for infectious diseases/cultures
Anxiety disorder Additional laboratory tests Exclude thyroid disease and pheochromocytoma
Cognitive dysfunction MRI Exclude infection/exclude infarction/exclude malignancy/exclude other neurological
diseases
Additional laboratory tests Vitamin B12, exclude DM, thyroid disease/serology testing for infectious diseases
Mood disorder,
psychosis
No specific laboratory tests are required
Neuroimaging only required if additional neurological symptoms or signs are present
Guillain Barre´ MRI spine Exclude myelopathies
Additional laboratory tests Serology testing for infectious diseases
Autonomic disorder Autonomic testing Assessment of severity and parts of autonomic nervous system involved
EMG and NCS Characterization of neuropathy
Additional laboratory tests Exclude DM, uremic neuropathy and vitamin deficiencies/plasma norepinephrine
levels/serology testing for infectious diseases/exclude celiac disease/AChR
Mononeuropathy Additional laboratory tests Exclude DM/ANCA/serology testing for infectious diseases
Myasthenia gravis MRI Exclude compression cranial nerves/signs of MS
CT scan Exclude thyroid disease
Additional laboratory tests Specific antibodies (AChR, MuSK, LRP4)/exclude thyroid disease
Cranial neuropathy MRI Exclude infection/exclude malignancy
Evoked potentials Characterization of neuropathy
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presence of generalized lupus activity, initiation of
immunosuppressive therapy is warranted (corticosteroids
alone or in combination with another immunosuppressant),
with the main objective of resolving/stabilizing symptoms.
On the other hand, anticoagulation and antiplatelet agents
are the mainstay of secondary prevention after ischemic
NPSLE, especially in the presence of aPL (Fig. 1) [38].
Some authors have suggested that when ischemic and
inflammatory NPSLE syndromes coexist, a broad therapy
approach with both immunosuppressive and anticoagula-
tion and/or antiplatelet therapy should be considered. In the
Leiden NPSLE clinic, a treatment algorithm was developed
based on available evidence and our own expertise,
although the treatment of NPSLE patients must always be
individually tailor made (Fig. 2; Table 4) [38, 47].
6.1 General Treatment
6.1.1 Symptomatic Therapy
The management of patients with NPSLE is multimodal.
In several NPSLE syndromes, symptomatic therapy is
Table 3 continued
Plexopathy MRI spine Exclude compression due to malignancy
Electrodiagnosis Characterization of plexopathy
Additional laboratory tests Vitamin B12, exclude DM, thyroid disease/serology testing for infectious diseases
Polyneuropathy EMG Characterization neuropathy
Punch skin biopsy Exclude small-fiber neuropathy if EMG normal
Laboratory tests Vitamin B12 and exclude DM
AChR ganglionic acetylcholine receptor autoantibody, aCL anticardiolipin antibodies, ANCA antineutrophil cytoplasmatic antibodies, AVM
arteriovenous malformation, CT computed tomography, DM diabetes mellitus, EEG electroencephalogram, EMG electromyogram, LAC lupus
anticoagulant, LP lumbar puncture, LETM longitudinally extensive transverse myelitis, LRP4 low-density lipoprotein receptor-related protein 4,
MRA magnetic resonance angiography, MRI magnetic resonance imaging, MS multiple sclerosis, MuSK muscle-specific tyrosine kinase, NCS
nerve conduction studies, NMO neuromyelitis optica, NPSLE neuropsychiatric systemic lupus erythematosus, PRES posterior reversible
encephalopathy syndrome, SLE systemic lupus erythematosus, TIA transient ischemic attack
Fig. 1 Therapeutic options in NPSLE. aCL anticardiolipin antibodies, b2GP I b2-glycoprotein I, LAC lupus anticoagulant, NPSLE
neuropsychiatric systemic lupus erythematosus
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needed. In SLE patients with mood disorders, psychosis,
seizure disorders, movement disorders, and headaches,
current drugs used to treat these symptoms are often the
first treatment step, without taking into account NPSLE as
the potential underlying cause. In mild NP manifestations,
this symptomatic therapy can be sufficient; however,
more severe NPSLE manifestations or inadequate
response to symptomatic treatment warrants additional
therapy with immunosuppressive and/or antithrombotic
medication.
Antidepressive and antipsychotic agents, as well as anx-
iolytics, are prescribed according to the standard indications
Fig. 2 Therapeutic approach for NPSLE based on available
evidence and data from the Leiden NPSLE cohort. A combination
of immunosuppressive therapy and secondary prevention may be used
in the same patient when both ischemic and inflammatory pathogenic
mechanisms are suspected. 1 In patients with mild symptoms,
symptomatic therapy may be sufficient, or glucocorticoids\0.5 mg/
kg/day ± azathioprine 2 mg/kg and re-evaluation of symptoms after
3–6 months may be considered. 2 In patients with severe NPSLE,
pulses of methylprednisolone 1 g/day intravenously for 3 days can be
indicated. 3 Prednisone in a tapering dose. 4 Prednisone\7.5 mg/day
when possible. Azathioprine or other DMARDs such as mycopheno-
late depending on expertise or other concomitant organ SLE
involvement. ACE angiotensin-converting enzyme, aCL anticardi-
olipin, ASA acetylsalicylic acid, APS antiphospholipid syndrome, CV
cardiovascular, DMARDs disease-modifying antirheumatic drugs, IV
intravenous, IVIG intravenous immunoglobulin, LAC lupus anticoag-
ulant, LDL low-density lipoprotein, NPSLE neuropsychiatric systemic
lupus erythematosus, SLE systemic lupus erythematosus
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in psychiatric disorders. Antiepileptic therapy is started
when high-risk features are present: second seizure ([24 h
after the first event), serious brain injury, brain structural
abnormalities (MRI), focal neurological signs, partial sei-
zure as the first seizure, and epileptiform EEG discharges.
Generalized seizures are usually managed with phenytoin or
barbiturates, and partial complex seizures are usually man-
aged with carbamazepine, clonazepam, valproic acid, or
gabapentin. Symptomatic therapy in movement disorders
consists of dopamine agonists. Nonsteroidal anti-inflam-
matory drugs can be added for symptomatic pain relief and
migraine treatment for specific headaches [38, 48].
6.1.2 Nonpharmacological Intervention
Cognitive complaints in SLE patients are common, with
most studies reporting a prevalence ranging from 17 to
66 % [26]; however, most cases of cognitive dysfunction
are mild and immunosuppressive therapy is not indicated
in these patients. Cognitive dysfunction has been asso-
ciated with psychosocial factors such as fatigue, sleep
deprivation, pain, depression, and anxiety. No consistent
evidence-based symptomatic therapy exists for cognitive
dysfunction in SLE. It has been reported that some
patients with depression and cognitive dysfunction may
benefit from antidepressants [49]. In patients who
reported cognitive dysfunction but were not globally
impaired on neuropsychological testing, the positive
effects of an 8-week psychoeducational group interven-
tion were reported to improve memory self-efficacy,
memory function, and the ability to perform daily
activities [50]. A study evaluating a 6-month psychoed-
ucational group intervention in a group of 34 SLE
patients also resulted in a significant and sustained
Table 4 Specific management per neuropsychiatric manifestation
Aseptic meningitis
Symptomatic therapy
Glucocorticoids and immunosuppressive therapy
Cerebrovascular disease
Consider thrombolysis
See algorithm in Fig. 2
High SLE activity or suspicion of cerebral vasculitis MRA:
glucocorticoids and immunosuppressive therapy
Demyelinating syndrome
Glucocorticoids and immunosuppressive therapy
Consider rituximab if MS overlap or doubtful diagnosis
Headache
Symptomatic therapy
Recurrence or association with high SLE activity: consider
glucocorticoids
Movement disorder
Dopamine
Infarcts on MRI and aPL negative – antiplatelet therapy
Infarcts on MRI and aPL positive – anticoagulants
Normal MRI and aPL positive – consider antiplatelet therapy or
anticoagulants
High SLE activity: add glucocorticoids and immunosuppressive
therapy
Myelopathy
Glucocorticoids and immunosuppressive therapy
Intense rehabilitation
Seizure disorders
First episode: antiepileptic therapy
Recurrence: chronic antiepileptic therapy
Infarcts in MRI and aPL negative – antiplatelet therapy
Infarcts in MRI and aPL positive – anticoagulants
Normal MRI and aPL positive – antiplatelet therapy or
anticoagulants
High SLE activity: glucocorticoids and immunosuppressive therapy
Acute confusional state
Glucocorticoids and immunosuppressive therapy
Table 4 continued
Anxiety disorder
Psychotherapy
Anxiolytics
Recurrence or association with high SLE activity: consider
glucocorticoids
Cognitive dysfunction
Psychotherapy and cognitive rehabilitation
Infarcts in MRI, aPL positive: consider antiplatelet therapy or
anticoagulants
Progressive or associated with high SLE activity: consider
glucocorticoids
Mood disorder
Psychotherapy
Antidepressants
Recurrence or association with high SLE activity: consider
glucocorticoids
Psychosis
Antipsychotic agents
Associated with high SLE activity: glucocorticoids and
immunosuppressive therapy
Guillain–Barre´
IVIG and plasmapheresis
Autonomic disorder
Glucocorticoids and immunosuppressive therapy. IVIG.
Plasmapheresis
Mononeuropathy (single/ multiplex), cranial neuropathy, plexopathy,
polyneuropathy
Symptomatic therapy: NSAIDs, gabapentin, pregabalin,
carbamazepine
Progressive or acute presentation: glucocorticoids and
immunosuppressive therapy. IVIG
Myasthenia gravis
Pyridostigmine
Glucocorticoids. IVIg. Thymectomy
aPL antiphospholipid antibodies, IVIG intravenous immunoglobulins,
MRA magnetic resonance angiography, MRI magnetic resonance imaging,
MS multiple sclerosis, NSAID nonsteroidal anti-inflammatory drugs, SLE
systemic lupus erythematosus
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improvement in coping skills of SLE patients and hence
in their quality of life [51].
6.2 Primary Prevention
6.2.1 Antimalarial Drugs
Hydroxychloroquine and chloroquine are 4-aminoquinoli-
nes, and quinacrine is an acridine derivative. The use of
antimalarials as a treatment for SLE became popular after
reports were first published in the 1950s [52]. Nowadays,
the prescription of hydroxychloroquine (200 or
400 mg/day) is considered mandatory in the treatment of
SLE, and is recommended during the whole course of the
disease, independently of severity, and even continued
during pregnancy. This therapy is extensively used for
cutaneous and musculoskeletal involvement [38, 53].
Widespread use of chloroquine and hydroxychloroquine
led to recognition of retinal toxicity as the most frequent
complication. Quinacrine differs from hydroxychloroquine
and chloroquine in that it has no recognized retinal toxicity.
Other known but uncommon antimalarial side effects are
dermatitis, gastrointestinal symptoms, leukopenia, throm-
bocytopenia, aplastic anemia and cardiotoxicity [54].
Moreover, these drugs are also known as a rare cause of
psychosis, and chloroquine has been associated with the
occurrence of epileptic seizures in patients with a history of
epilepsy [55, 56]. Although no studies specifically address
its effect on NP symptoms, a preventive role of these drugs
in CNS lupus has been suggested, especially in cere-
brovascular disease [46, 57].
A reduction of mortality in multiple SLE cohorts, and
reduced accrual of damage, was shown in SLE patients
treated with antimalarials [58]. Moreover, several studies
using antimalarials have demonstrated that immunologic
effects can reduce the risk of CVD, such as improvement of
dyslipidemias, prevention of diabetes, and reducing aPL
titers [59–62]. In an SLE cohort study of 1150 patients,
antimalarials had an independent protective effect on the
development of metabolic syndrome over time, showing its
potential as an atheroprotective drug in these patients [63].
Antithrombotic effect is another known additional ben-
efit of antimalarials. Jung et al. demonstrated how anti-
malarial drugs were associated with a 68 % reduction in
the risk of all thrombovascular events in SLE [64]. Other
prospective SLE studies have also found a positive effect
of hydroxychloroquine on reducing the risk of future
thrombotic events [60, 65].
Another potential benefit attributed to antimalarial drugs
in SLE is the protective effect against seizures, such as was
reported in the LUMINA cohort [66]. Recently, another
cohort study on 1631 SLE patients has confirmed this
association. The mechanism of how the protection occurs is
unknown [67].
6.2.2 Statins
Statins act by competitive inhibition of the hydrox-
ymethylglutaryl-coenzyme A (HMG-CoA) reductase
enzyme, blocking the transformation of HMG-CoA into
mevalonate and subsequently inhibiting cholesterol syn-
thesis [68]. This therapy is used extensively to treat
hypercholesterolemia. A reduction in levels of low-density
lipoprotein (LDL)-cholesterol have demonstrated a marked
benefit in the prevention of CVD and a dramatic reduction
of morbidity and mortality in established CVD [68, 69].
Some immunomodulating effects, such as reduction of
inflammatory cytokines and adhesion molecules, preven-
tion of endothelial cell activation induced by aPL, inhibi-
tion of T-cell function, and reduction of the number and
activity of inflammatory cells in atherosclerotic plaque
have been attributed to statins [68, 70, 71]. Statins may
improve the regulation of the inflammatory processes
involved in atherosclerosis [72].
All these properties have been reported to be of interest
in SLE since this disease is associated with an increased
risk of accelerated atherosclerosis not fully explained by
traditional risk factors [35]. For some authors, SLE is
considered a coronary heart disease risk factor equivalent
to diabetes. It has been proposed that as the 10-year car-
diovascular risk charts do not take lupus into account as a
risk factor, it results in undertreatment of these patients.
Based on this, Elliot and Manzi, as well as other authors,
have proposed an LDL goal of \100 mg/dl in all SLE
patients and\70 mg/dl for those SLE patients with sub-
clinical CVD, known stroke/transient ischemic attack
(TIA) or other cardiovascular event, peripheral vascular
disease, or diabetes [73, 74]. However, to date no studies
have demonstrated the efficacy of statin therapy as primary
or secondary cardiovascular prevention in SLE patients.
The Lupus Atherosclerosis Prevention Study, a 2-year trial
of atorvastatin in 200 adult patients with SLE without
clinical CVD, showed no benefit in the primary (coronary
artery calcium) or secondary (carotid intima media thick-
ness and carotid plaque) atherosclerosis outcomes [75].
The APPLE trial, a recently published 3-year prospective
study on pediatric SLE, reported no benefit of atorvastatin
use on preclinical CVD markers [76].
From our point of view, and as other authors have
pointed out, the lack of evidence does not support the
widespread use of statins in all SLE patients as primary
prevention. Subsequently, they recommend the use of sta-
tins in SLE patients with hyperlipidemia who meet criteria
for their use based on standard CVD guidelines such as the
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National Cholesterol Education Program [77]. Further-
more, SLE patients with a stroke or TIA presumed to be of
atherosclerotic origin must be treated according to the use
of the American Stroke Association Guidelines. The use of
statins is recommended in these patients when the LDL
cholesterol level is C100 mg/dL. Statin therapy may also
be considered when the LDL cholesterol level is\100 mg/
dL, but with less levels of evidence [78].
6.3 Management of Inflammatory NPSLE
6.3.1 Corticosteroids
Glucocorticoids are 21-carbon steroid hormones. The bio-
logical effects of glucocorticoids are mediated via the glu-
cocorticoid receptor. These hormones are involved in the
regulation of the immune response and inflammation, and
also play an important role in various metabolic processes.
Glucocorticoids, especially prednisone, have been the hall-
mark medication for SLE. This therapy offers the most
immediate anti-inflammatory effect of all immunosuppres-
sive therapies and is subsequently the more widely used
therapy to control mild–severe flares of SLE. The basis for
the use of different dosages of glucocorticoids in a specific
clinical setting in SLE is essentially empirical [79]. Gluco-
corticoids are also known to induce an important number of
undesirable side effects, including, among others, hyperten-
sion, dyslipidemia, osteoporosis, cataracts, glaucoma, elec-
trolyte alteration, diabetes, Cushing’s syndrome, peptic ulcer,
risk of infection, and reactivation of latent viruses. Overall,
prolonged application is a high-risk factor for these side
effects, whereas total dose is of secondary importance [80].
Furthermore, several NP disturbances have been related to
the use of glucocorticoids. For example, approximately 10 %
of patients treated with 1 mg/kg/day or more of prednisone
will have a glucocorticoid-induced psychiatric disease.
Depression, hypomania, and overt psychosis are known
glucocorticoid-induced psychiatric manifestations. Symp-
toms usually occur within 8 weeks of initiation or augmen-
tation of glucocorticoids and resolve completely in most
cases through dose reduction, which may help in the differ-
entiation with NPSLE [81].
In NPSLE patients, although corticosteroids are com-
monly used when NPSLE is thought to reflect an inflam-
matory process, this practice can only be substantiated by
clinical experience [38]. Despite the lack of solid evidence,
in severe NPSLE manifestations an accepted practice
consists of 1 g of methylprednisolone intravenously for 3
consecutive days followed by prednisolone orally (starting
dose 1 mg/kg/day), with a tapering scheme of
3–12 months. In less severe manifestations, the starting
dose is usually 0.5–1 mg/kg/day, and tapering schemes are
very diverse.
Although the benefits of glucocorticoids in an acute
setting are unquestionable, some studies have addressed the
important influence of corticosteroids, especially prolonged
use, on future damage accrual in SLE patients [82–84].
Glucocorticoids may aggravate underlying metabolic
abnormalities and other factors contributing to the risk of
clinical accelerated atherosclerosis, which may lead to
early cerebrovascular disease. Zonana-Nacach et al.
showed how each 2-month exposure to high-dose pred-
nisone was associated with a 1.2-fold increase in the risk of
stroke in SLE [82]. Other authors have suggested that doses
\7.5 mg/day, as well as methylprednisolone pulses, may
not be associated with damage accrual [83].
6.3.2 Cyclophosphamide
As an alkylating agent, cyclophosphamide adds an alkyl
group to DNA, thereby interfering with DNA replication.
Cyclophosphamide is a prodrug that is converted by liver
cytochrome 450 enzymes to its metabolite 4-hydroxy
cyclophosphamide. Both the dose and duration of therapy
will influence the degree of inhibition of immune function.
Cyclophosphamide is used for the most serious SLE
involvements [85]. In SLE patients, cyclophosphamide is
mostly administered in an intermittent intravenous sched-
ule instead of oral treatment. This was established by two
trials performed at the National Institutes of Health (NIH)
[86, 87]. The so-called NIH regimen has been used for
decades in severe SLE flares. This regimen consists of
monthly (for 6 months) and then quarterly (for up to 1 year
after complete remission) doses of 0.75–1.5 g/m2 intra-
venous cyclophosphamide, combined with intravenous
methylprednisolone. In order to minimize the side effects
of this drug, low-dose intravenous regimens (six fortnightly
pulses of a fixed dose of 500 mg) were later introduced in
patients with lupus nephritis. Ten-year follow-up data of
the Euro-Lupus Nephritis Trial comparing both doses of
cyclophosphamide showed that this low-dose protocol
achieved results comparable to the NIH regimen [88].
Cyclophosphamide has significant side effects. Common
complications are alopecia, nausea and vomiting, and bone
marrow depression. Although severe myelotoxicity is rare,
myelosuppression consisting primarily of leukopenia is
probably the most significant of the cyclophosphamide-in-
duced toxicities. Leukopenia and granulocytopenia increase
the patient’s risk of infection [89, 90]. Other organ-specific
toxicities of cyclophosphamide are hemorrhagic cystitis,
cardiotoxicity, interstitial pneumonitis, pulmonary fibrosis,
and cervical intraepithelial neoplasia [91]. Azoospermia and
ovarian failure are also well-documented consequences of
long-term therapy. The latter association is largely depen-
dent on its cumulative dose, and the effect is strongerwith the
patient’s increasing age [92, 93].
Therapeutic Approaches in NPSLE 469
Severe NPSLE manifestations, mainly CNS involve-
ment, have been treated with cyclophosphamide. Several
case series have described positive effects of treatment
with cyclophosphamide in severe NPSLE manifestations in
both adults and children [94, 95]. A report from Mok et al.
demonstrated a favorable response of 13 patients with
lupus psychosis to 6 months of treatment with oral
cyclophosphamide (1–2 mg/kg/day) and oral prednisone
(1 mg/kg/day), with the dose tapered gradually, followed
by azathioprine (1–2 mg/kg/day) [96]. A retrospective
study of 31 NPSLE patients suggested patients benefited
from concomitant glucocorticoids and monthly intravenous
cyclophosphamide (250–1000 mg/m2) [97]. Ramos et al.
retrospectively analyzed 25 NPSLE patients with CNS
involvement. All patients were treated with weekly low-
dose cyclophosphamide pulses (500 mg/m2) and all but
one patient achieved a good response after a mean of
11 days without major side effects [98]. Stojanovich et al.
conducted a study on 60 NPSLE patients and compared the
outcomes of two groups, one receiving monthly low-dose
intravenous cyclophosphamide (200–400 mg/m2) plus
prednisone versus prednisone alone. They concluded that
patients treated with cyclophosphamide showed more
clinical and electrophysiological improvement on cerebral
function [99].
Cyclophosphamide is the only therapy tested in a small,
randomized controlled clinical trial in NPSLE. This trial
compared intravenous methylprednisolone with intra-
venous cyclophosphamide. All patients received methyl-
prednisolone 1 g/day for 3 days as induction treatment.
This was followed by methylprednisolone 1 g/month for
4 months, then bimonthly for 6 months and subsequently
every 3 months for 1 year, or cyclophosphamide 750 mg/
m2 monthly for 1 year and then every 3 months for another
year. Furthermore, oral prednisone (1 mg/kg/day) was
started on the fourth day of treatment (1 mg/kg/day), for no
more than 3 months, and tapered according to disease
activity/remission. Treatment response, defined as 20 %
improvement from basal conditions by clinical, serological,
and specific neurological measures at 24 months, was
observed in 94.7 % (18/19) of patients using intravenous
cyclophosphamide compared with 46.2 % (6/13) of
patients in the methylprednisolone group. Other benefits of
cyclophosphamide were a reduction in prednisone
requirements and electroencephalographic improvement.
No statistically significant differences in adverse effects
were reported between the groups [100].
A recent Cochrane systematic review remarked that this
study was the only very-low-quality evidence that
cyclophosphamide is more effective in reducing NPSLE
symptoms compared with methylprednisolone [101].
Besides the lack of good evidence, in clinical practice it is
common to treat severe manifestations of NPSLE thought
to reflect an inflammatory/neurotoxic process with an
induction regimen of cyclophosphamide (500–750 mg/
m2/month) in combination with glucocorticoids (pred-
nisolone 1 mg/kg/day, with a tapering schedule of
3–6 months with or without a previous 3 days of intra-
venous methylprednisolone 500–1000 mg/day). After
6 months of therapy, cyclophosphamide can be continued
in the same dose every 3 months for 18 months, or main-
tenance therapy during 1 year with other immunosuppres-
sive therapy, for example azathioprine, may be considered
to prevent recurrence [38].
From our point of view, since there is no evidence to
support one or the other regimen, azathioprine may be a
better option due to its better side effect profile; however,
this decision must be taken based on expert opinion after
evaluation of an adequate response to induction therapy
with cyclophosphamide, taking into account the type of
NPSLE syndrome, other concomitant organ SLE involve-
ments, age of the patient, and the desire to become preg-
nant in the future.
6.3.3 Azathioprine
Azathioprine is a prodrug that is rapidly converted to
mercaptopurine and methylnitroimidazole by thiopurine
methyltransferase (TPMT). Mercaptopurine is known to
inhibit several enzymatic process involved in purine syn-
thesis, which affect both cellular and humoral immune
functions [102].
The positive effects of this drug in SLE patients, espe-
cially in the prevention of flares, have been previously
described in the 1970s [103]. Nowadays, azathioprine
(2–3 mg/kg/day) is mainly used in SLE patients presenting
with arthritis, mucocutaneous manifestations, and serositis,
and as maintenance therapy in lupus nephritis [57].
The side effects of azathioprine include bone marrow
suppression, hepatotoxicity, gastrointestinal intolerance,
and a mild increased risk for infections [104]. Furthermore,
in the absence of TPMT activity, patients are likely to have
higher concentrations of thioguanine nucleotides, which
can pose an increased risk of severe life-threatening
myelosuppression; therefore, determination of TPMT
activity before initiating therapy with azathioprine is rec-
ommended by some authors [102].
The effect of azathioprine on NP manifestations in SLE
has been scarcely studied. Due to its relatively mild side
effect profile, azathioprine is frequently used for mainte-
nance or as a glucocorticoid-sparing agent; however, con-
trolled trials are lacking. A study including 68 SLE patients
with a poor prognosis due to renal or NP manifestations
showed that the 54 patients treated with azathioprine had a
significantly improved long-term survival and fewer hos-
pitalizations compared with those who did not receive this
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drug. The authors remarked on the importance of this
therapy in the maintenance of clinical remission and inhi-
bition of further deterioration of CNS function [105].
However, in a randomized trial of azathioprine (3–4 mg/
kg/day plus prednisone initially) versus prednisone
(60 mg/day initially) in 24 patients with life-threatening
SLE, no significant short-term benefit was observed for
azathioprine on NP and other SLE manifestations [106].
A single-center cohort study by Lim et al. reported the
clinical course and response to immunosuppressive treat-
ment of 53 children with psychiatric manifestations
attributed to SLE (all with cognitive dysfunction and 40
with psychosis). Eighteen of 32 patients treated with aza-
thioprine required a change to cyclophosphamide due to
poor response; however, none of the patients receiving
cyclophosphamide required a change [107].
One open-label trial has been conducted using azathio-
prine as maintenance therapy after 6 months of oral
cyclophosphamide and oral prednisone in a very small case
series of 13 patients with lupus psychosis. After a follow-
up period of 86 ± 51 months, only one patient (8 %) had a
relapse of psychosis and three patients developed other NP
symptoms [96]. In patients with psychiatric disorders in the
context of generalized SLE activity, induction therapy with
glucocorticoids and cyclophosphamide followed by main-
tenance with azathioprine may result in a significant
improvement (60–80 % response), although relapses may
occur (up to 50 %) [38].
In addition to these results, and although the use of this
therapy in NPSLE is not supported by current evidence,
azathioprine is widely used in clinical practice as mainte-
nance therapy after cyclophosphamide induction in severe
NPSLE symptoms, and as the first option in mild NPSLE
symptoms as a glucocorticoid-sparing agent. Further stud-
ies are needed.
6.3.4 Mycophenolate Mofetil
Mycophenolate mofetil is a prodrug of mycophenolic acid,
an inhibitor of lymphocyte proliferation via reversible
inhibition of inosine-50-monophosphate dehydrogenase,
which is critical for the de novo synthesis of guanosine
nucleotides. Mycophenolic acid suppresses antibody for-
mation, cell-mediated immune response, the expression of
adhesion molecules, and recruitment of lymphocytes and
monocytes to sites of inflammation [108].
Historically, this drug has been used to reduce acute and
chronic rejection in allograft recipients. In SLE patients,
mycophenolate mofetil is widely used as the first-line
option for both induction and maintenance therapy of lupus
nephritis [110, 111]. Several observational studies have
suggested the potential benefit of mycophenolate mofetil in
nonrenal manifestations of SLE, especially in
hematological and dermatological manifestations; how-
ever, none focused on NP manifestations [112].
Mycophenolate mofetil and mycophenolic acid are
administered orally at a dose of 1000–3000 mg/day and
1080–1440 mg/day, respectively. The main adverse effects
of mycophenolate mofetil are gastrointestinal intolerance
(nausea, abdominal pain, mild to moderate diarrhea), bone
marrow suppression, and infections [109].
Ginzler et al. analyzed, as a secondary endpoint, the
nonrenal flares of the Aspreva Lupus Management Study,
which compared the effect of mycophenolate mofetil with
intravenous cyclophosphamide in 370 patients with lupus
nephritis. Three NPSLE patients were treated with
mycophenolate mofetil and prednisolone after 3-day
methylprednisolone pulses; two patients responded par-
tially, whereas one had complete recovery. Moreover, two
patients in the cyclophosphamide group developed new
neurologic manifestations versus none in the mycopheno-
late mofetil group [113]. In a SLE cohort study of 75
patients who were all treated with mycophenolate mofetil,
neurologic manifestations improved in two of two patients,
but new neurologic manifestations occurred in six patients
[114].
Other authors have described individual cases or small
case series of NPSLE patients treated with mycophenolate
mofetil, mainly as maintenance therapy after initial treat-
ment with cyclophosphamide [109, 115–118]. Three
patients with myelopathy were treated with mycophenolate
mofetil as the first immunosuppressive agent. One patient
did not respond, one patient achieved partial recovery, and
the other patient achieved complete recovery [109, 115].
Saison et al. published a series of 20 SLE patients with
myelopathy. In nine patients, mycophenolate mofetil was
chosen as maintenance therapy. Four of these patients
relapsed at least once in the first 2 years [119].
In general, the efficacy of this drug in NPSLE patients is
very modest. Furthermore, since most patients were
simultaneously or previously treated with high-dose glu-
cocorticoids, intravenous immunoglobulins (IVIGs), or
another immunosuppressant, it is difficult to draw any
conclusions.
6.3.5 Methotrexate
Methotrexate is a folic acid antagonist. The polyglutamated
derivatives of methotrexate are potent inhibitors of various
enzymes, including dihydrofolate reductase and
5-aminoimidazole-4-carboxamide ribonucleotide trans-
formylase. Among the multiple immunosuppressive
effects, the inhibition of interleukin (IL)-1, as well as an
effect on proteolytic enzymes, has been described.
Methotrexate is usually administered orally, subcuta-
neously, or intramuscularly. Methotrexate is routinely used
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in SLE patients with musculoskeletal and skin manifesta-
tions. It has also been administered intrathecally or into the
cerebral ventricles, particularly in patients with CNS
tumors. In these cases, 10 mg methotrexate and 10 mg
dexamethasone is diluted by 3 ml normal saline and
injected by conventional lumbar puncture. This route of
administration may solve the problem that this drug may
have to get through the BBB and increase the methotrexate
drug concentration in CSF. The more common side effects
of methotrexate include gastrointestinal symptoms, stom-
atitis, increased levels of liver enzymes and mild cytopenia.
Furthermore, severe complications such as liver fibrosis,
interstitial pneumonitis, and severe pancytopenia have been
reported [120, 121].
This drug is used very rarely in NPSLE and evidence is
limited to several case series reporting the effect of
intrathecal methotrexate. Valesini et al. reported the
improvement of three NPSLE patients after a combination
of intrathecal methotrexate and dexamethasone [121].
A Chinese group published several reports on the same
cohort. A total of 109 patients received a combination of
intrathecal methotrexate and dexamethasone (one to five
injections), and showed an association with a positive
outcome [122]. Wang et al. reported an effectiveness rate
of 89 % of methylprednisolone treatment combined with
intrathecal methotrexate in 36 NPSLE patients [123]. In
addition to these results, intrathecal administration of
methotrexate is not considered common practice and is
limited to a few centers [38].
6.3.6 Cyclosporin A
Cyclosporin A is a calcineurin inhibitor initially
derived from a fungus; it depresses T-cell activity by
inhibiting transcription of IL-2 and other cytokines.
Cyclosporin A has immunosuppressive properties and
has been used in patients with SLE at a daily dose of
2.5–3 mg/kg [124]. The place of cyclosporin A in the
treatment of SLE patients is limited and most data
regarding these agents come from experience with
lupus nephritis. This therapy is known to cause side
effects such as hypertension, deterioration of renal
function, and hypertrichosis [125].
No studies explicitly describe the effect of cyclospor-
in A on NP symptoms in SLE. Cyclosporin A, together
with therapeutic plasma exchange (TPE), has been used in
18 NPSLE patients with organic brain syndrome and psy-
chosis. When this combination was added to the previous
standard therapy including corticosteroids and azathioprine
or cyclophosphamide during a flare, earlier improvement in
NP symptoms was achieved. However, the real efficacy of
plasma exchange or cyclosporin A remains unknown due
to the concomitant use of both therapies [126].
6.3.7 Rituximab/Anti-CD20
Rituximab is a chimeric monoclonal antibody directed
against the B-cell-specific antigen CD20. B-cell depletion
is achieved by rituximab through different mechanisms
such as antibody-dependent cell-mediated cytotoxicity,
complement-dependent cytotoxicity, and induction of
apoptosis. The use of B-cell depletion therapy in SLE is
based on the aspect that B cells play a central role in the
pathogenesis of SLE, as antigen-presenting cells and in the
production of autoantibodies, cytokines, and chemokines.
Currently, rituximab is widely used as an alternative ther-
apy in patients with active SLE who are nonresponsive to
standard immunosuppressive therapy [127].
Two randomized controlled trials (RCTs) on rituximab
in SLE patients, one with renal involvement [the Lupus
Nephritis Assessment with Rituximab (LUNAR) trial] and
the other without renal involvement [the Exploratory Phase
II/III SLE Evaluation of Rituximab (EXPLORER) trial]
failed to find superiority of rituximab over standard
immunosuppressive regimens (glucocorticoids, cyclophos-
phamide, and mycophenolate mofetil) in mild to moder-
ately active SLE. In these studies, severe and/or refractory
patients were not included [128, 129]. On the other hand,
the efficacy and safety of rituximab in the treatment of
nonrenal SLE has recently been analyzed in a systematic
review including one RCT, two open-label studies and 22
cohort studies, with a total of 1231 patients. Rituximab was
shown to be safe and effective in the treatment of nonrenal
SLE, especially in terms of disease activity, immunologic
parameters, and corticosteroid-sparing effect [130]. The
efficacy of rituximab in NPSLE was not assessed in the
previous studies; however, in a substantial number of case
reports and some open-label studies, good efficacy of
rituximab was shown in refractory cases of NPSLE.
Tokunaga and colleagues reported a response rate of
100 % in a series of ten severe refractory NPSLE patients
treated with rituximab [131]. Narvaez and colleagues
summarized all published data concerning adult patients
with refractory NPSLE. A clinical response was observed
in 85 % (29/34) of patients, classified as complete response
in 50 % (17/34) and partial response in 35 % (12/34) of
patients. However, 45 % of these patients relapsed after a
median of 17 months despite maintenance therapy. Dif-
ferent therapeutic regimens of rituximab were used. The
most frequently used regimen was 1000 mg doses sepa-
rated by 15 days. Different dosing schedules appeared to
show no difference in response, tolerability, or side effects.
In all cases, rituximab was administered together with
corticosteroids [132]. A recent case series on 18 pediatric
NPSLE patients showed promising effect of rituximab. The
authors divided the benefit into definite (five patients),
probable (seven patients), possible (five patients) and no
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effect (one patient) [133]. Long-term information regarding
rituximab therapy in NPSLE is scarce. Current data support
the use of rituximab as a second-line therapy in patients
with severe refractory NPSLE but additional controlled
studies are needed to define the exact place of rituximab in
the therapeutic regimen for NPSLE.
6.3.8 Intravenous Immunoglobulins
IVIGs constitute a mixture of natural antibodies of IgG
subclass derived from the blood of healthy donors [134]. In
SLE patients, the beneficial effects of IVIGs are thought to
be due to (1) suppression of the function of autoreactive B
lymphocytes and neutralization of pathogenic autoanti-
bodies produced by these cells; and (2) inhibition of type I
IFN-mediated differentiation of dendritic cells and sup-
pression of endocytosis of nucleosomes [135].
Available evidence for the efficacy of IVIGs in SLE is
limited and is derived from case reports and case series.
Current indications proposed for IVIGs in SLE are severe
cases nonrespondent to conventional immunosuppressive
drugs, patients with active SLE and concomitant infection,
and use as a corticosteroid-sparing agent when SLE can be
controlled only with high-dose glucocorticoids. Further-
more, IVIGs can be safely used during pregnancy, without
teratogenic risk, and might be a good choice in severe and
life-threatening cases. In SLE patients, IVIGs have been
administered as 2 g/kg, with divided doses over 2–5 days
as the more commonly practiced regimen [136, 137]. The
occurrence of adverse effects attributed to IVIGs is
reported in up to 20 % of patients. The majority of side
effects described are mild and self-limited (i.e. headaches,
fever, flushing, chills, arthralgia, back pain, and myalgia)
and do not require discontinuation of therapy. Other serious
anecdotal systemic reactions, such as thromboembolic
complications, have also been described [136, 138].
Based on case reports/series and retrospective studies,
IVIGs have been successfully used to treat NPSLE
patients with a broad spectrum of symptoms, including
CNS manifestations (acute confusional syndrome, sei-
zures, headache, chorea, psychosis), PNS manifestations
(chronic inflammatory demyelinating polyneuropathy,
Guillain–Barre´, peripheral neuropathy associated with
vasculitis), and psychiatric symptoms (psychosis,
depression, mood disorder) [137, 139]. Camara and
colleagues recently reported a series of 52 SLE patients,
including 11 patients with nervous system involvement
treated with IVIGs. Among these patients, six had CNS
involvement and five had peripheral neuropathy. After
IVIG treatment, eight of these patients experienced
improvement (four total remission and four partial
responses), and three (CNS vasculitis, peripheral neu-
ropathy, and other with a nonspecified NPSLE) did not
respond to this therapy [139]. In general, in the majority
of the NPSLE cases reported to date, IVIGs were
administered because of no response after corticosteroid
pulses, failure of or contraindication for standard
immunosuppressive therapy, or the presence of a con-
comitant infection. As seen in other SLE manifestations,
the beneficial effects of IVIGs on NP symptoms were
rapidly achieved and patients did not experience any
relapse after the last infusion [137, 139, 140]. IVIGs may
be used in severe refractory NPSLE not responding to
conventional immunosuppression, or even as the first-
choice agent when patients are pregnant or if symptoms
are life-threatening and a concomitant infection is pre-
sent. Future RCTs are needed for identifying the effi-
cacy, safety, optimal dose, and duration of therapy, to
support the evidence-based use of IVIGs in NPSLE
patients.
6.3.9 Therapeutic Plasma Exchange
TPE is an extracorporeal blood purification technique
designed for the removal of large molecular weight sub-
stances from the plasma. Either fresh frozen or stored
plasma are used to replace large quantities of plasma from
a patient by passing venous blood through an extracorpo-
real continuous flow centrifugation device. The rationale of
this technique is that removal of substances will reduce
further damage and may permit reversal of the pathologic
process [141]. How this therapeutic procedure works
exactly in SLE patients remains a matter of debate [142].
TPE is an expensive complex technique that requires
specific equipment and experience. On the other hand, the
technique is relatively safe. Complications are minor and
include mild allergic reactions, fever, and hypocalcemic
symptoms such as paresthesias, nausea, and cramps.
Potentially life-threatening adverse reactions are rare
(\0.15 %) [142, 143].
Although TPE has been used to treat several SLE
manifestations with beneficial effects, its use in clinical
practice is limited. Apheresis is accepted by the American
Society for Apheresis (ASFA) as second-line therapy,
either as standalone treatment or in conjunction with other
modes of treatment, although the evidence is low [144].
TPE has been used alone or in combination with other
immunosuppressants as adjuvant therapy in patients with
NPSLE. It has been suggested that TPE modulates humoral
components of the immune response removing autoanti-
bodies and/or immune complexes, while immunosuppressive
therapy suppresses de novo antibody production [144, 145].
Neuwelt reviewed 26 SLE patients with CNS involve-
ment treated with TPE alone or in combination with
cyclophosphamide. After this therapy, 74 % of patients
improved, 13 % stabilized, and 13 % progressed,
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highlighting a potential benefit of TPE in refractory or
critically ill patients not responding to cyclophosphamide
[145]. A retrospective study on 13 patients with NPSLE
flares undergoing TPE showed complete remissions in
54 % of patients and partial remissions in 46 % of patients.
All but one patient had been administered cyclophos-
phamide and adjuvant plasma exchange during the same
week [146].
TPE and cyclosporine were used in a prospective trial of
28 SLE patients (18 patients with organic brain syndrome
and psychosis). This combination was added to the previ-
ous therapy (glucocorticoids and azathioprine or
cyclophosphamide) during severe SLE flares. Earlier
improvement in organ involvement, including rapid reso-
lution of NP symptoms, was achieved; however, the real
efficacy of TPE is not known due to the concomitant use of
cyclosporine [126].
The ASFA guidelines suggest that a daily or every other
day course (1–1.5 total plasma volumes) for three to six
times is sufficient to see response in patients with lupus
cerebritis. The guidelines also set out the treatment of acute
inflammatory demyelinating disease, but there are no rec-
ommendations regarding myelopathy in SLE. In this par-
ticular case, TPE has been successfully used in severe
cases; however, its real efficacy in these patients remains to
be clarified since most of the successful cases reported used
concomitant immunosuppressive therapy [146, 147]. TPE
may also have an indication in other neurological entities
related to SLE, such myasthenia gravis and Guillain–Barre´
syndrome. Although there are no specific recommendations
for these NP symptoms, good functional outcomes have
been reported when TPE has been added to immunosup-
pressive therapy in SLE patients with these complications
[144, 148–150].
In conclusion, TPE in combination with other
immunosuppressive therapy has acceptable toxicity and
may be a good alternative in severe NPSLE; however,
controlled trials are needed to better define the role of this
therapy in these patients.
6.3.10 Hematopoietic Stem Cell Transplantation
Autologous hematopoietic stem cell transplantation
(AHSCT) has emerged as an effective treatment modality
in intractable SLE patients. AHSCT can achieve sustained
clinical and immunologic remissions (50–70 % disease-
free survival [DFS] at 5 years) even in patients with severe
disease who are not responding to any other conventional
immunosuppressive therapy [151]. The aim of this therapy
is resetting the patient’s immune system by (1) depletion of
autoreactive memory cells; and (2) reconstitution of the
immune system by a normalized repertoire of graft-derived
younger T cells [152]. Peripheral blood is the preferred
source of hematopoietic stem cells, and the combination of
cyclophosphamide (2–4 g/m2), antithymocyte globulin
(30 mg/kg), and granulocyte colony-stimulating factor (G-
CSF; 5 lg/kg) represents the most used ablation/mobi-
lization strategy [151, 152].
AHSCT is associated with an increased risk of short-
term mortality, attributable in most cases to infectious
complications or disease flares. Transplant-related mortal-
ity ranges from 0 to 25 % [153]. Furthermore, it has been
reported that SLE patients have the highest 100-day
transplant-related mortality and highest 5-year post-trans-
plant mortality compared with other autoimmune diseases;
therefore, it is important that the risk:benefit ratio is opti-
mized in these patients [154].
According to recent literature, more than 200 patients
have received autologous stem cell transplants as therapy
for lupus refractory to aggressive standard immunosup-
pressive therapy [151]. The largest number of cases pub-
lished come from the European Group for Blood and
Marrow Transplantation (EBMT) registry (n = 85), and a
North American single-center experience (n = 50). The
probability of 5-year DFS in both studies was approxi-
mately 50 %. Furthermore, patients not achieving sustained
remission had better response to therapies that had previ-
ously failed [151, 154, 155].
Among the 50 SLE patients undergoing AHSCT reported
by Burt and colleagues, 32 patients presented with any CNS
involvement (seizures, psychosis, headache, aseptic menin-
gitis, focal deficits, TIA, or myelopathy). In 18 cases, CNS
involvement was the primary indication for AHSCT. No
specific data regarding the outcome of NPSLE patients were
reported; however, in general the disease activity signifi-
cantly improved and remained significantly lower for up to
5 years after AHSCT [155]. Data from the EBMT registry
have been reported in two articles, depending on the period
of recruitment [156, 157]. Jayne and colleagues reported that
46 % of SLE patients recruited from 1995 to 2002 had CNS
involvement. The frequency of CNS lupus activity declined
to\5 % after AHSCT and only one patient developed new
CNS disease post-AHSCT [156]. Among the 28 SLE
patients reported to the EBMT registry between 2001 and
2008, 12 had neurologic disorder. The 3-year DFS, which
was defined as the time interval from ASCT to either relapse
or death, was 38 ± 15 % in NPSLE patients. Overall sur-
vival and DFS were not associated with the presence of
neurologic or any other involvement before AHSCT [156].
Other authors have also reported long-standing clinical
remission in NPSLE treated with AHSCT but the results are
limited to case reports or small series [152, 157]. In addition
to the improvement in overall lupus activity and serological
status, AHSCT has been reported to reverse antiphospho-
lipid syndrome (APS). Levels of aCL and LAC markedly
improved or normalized after transplantation in a high
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proportion of patients [158]. Burt and colleagues reported
that of 22 patients receiving anticoagulation, 18 were able to
discontinue this therapy a mean of 4 months after AHSCT,
and 78 % remained free of subsequent thrombotic events
[155].
AHSCT has been used as a salvage therapy for patients
with severe NPSLE refractory to intense standard
immunosuppressive therapy. In spite of the promising rates
of success, more RCTs are needed in SLE patients in order
to establish criteria for patient selection and the exact role
of this therapy.
6.4 Management of Ischemic NPSLE
and Secondary Prevention
6.4.1 Antiplatelet Treatment
The disruption of atherosclerotic plaques leads to
enhanced platelet deposition and, subsequently, to the
formation of arterial thrombus, which can precipitate in
an acute cerebrovascular event. Since platelets have been
described as key cellular components of arterial occlusive
thrombi, acetylsalicylic acid, a drug with a potent effect to
diminish platelet aggregation, is intended to have a sig-
nificant impact on morbidity and mortality [159].
Atherosclerosis has been described as occurring prema-
turely in SLE patients and being independent of tradi-
tional risk factors for CVD [35]. Platelet activation is
increased in SLE patients compared with controls and
may have a role in accelerated atherosclerosis [160].
Furthermore, the simultaneous presence of SLE and aPL
antibodies, namely LAC and isolated persistently positive
aCL at medium–high titers, has been associated with an
increased risk of thrombosis. Tektonidou and colleagues
reported that low-dose acetylsalicylic acid had a mild
protective role against thrombosis in aPL-positive SLE
patients [161]. Experts in APS recommend the use of low-
dose acetylsalicylic acid in SLE patients with a positive
LAC or isolated persistent aCL at medium–high titers as
primary thromboprophylaxis when no major contraindi-
cations are present [162].
As secondary thromboprophylaxis, therapy depends on
the presence of definite APS. In patients without aPL or
with aPL who do not fulfill the criteria for APS, acetyl-
salicylic acid (50–325 mg/day) monotherapy, the combi-
nation of acetylsalicylic acid and extended-release
dipyridamole, and clopidogrel 75 mg monotherapy are
acceptable options for initial therapy. These options are
recommended as the first choice over double therapy
(acetylsalicylic acid/clopidogrel) or anticoagulants [162,
163]. In patients who have had a second cerebrovascular
event while receiving acetylsalicylic acid, alternative
antiplatelet agents such as clopidogrel are often considered;
however, no single agent or combination has been well-
studied in the general population or in SLE patients [163].
In SLE patients with stroke fulfilling the criteria for
APS, optimal treatment is a matter of ongoing debate. Sole
antiplatelet treatment has been proposed as an option,
while other authors support the use of combined anti-
platelet treatment and lower intensity anticoagulation [in-
ternational normalized ratio (INR) 2.0–3.0] or high-
intensity oral anticoagulation (INR[3.0) [162].
6.4.2 Anticoagulation
Anticoagulant drugs have demonstrated its effectiveness
for the prevention and treatment of venous and arterial
thromboembolism; however, their use is also associated
with an increased risk for bleeding, and in some adminis-
tration routes, especially oral, management can be chal-
lenging. The use and benefits of anticoagulant therapy in
both primary and secondary prevention of ischemic cere-
brovascular disease in the subset of SLE patients with aPL
or APS remains controversial [164]. Cuadrado and col-
leagues recently reported a 5-year prospective, random-
ized, open, controlled trial on 166 SLE patients with aPL
randomly receiving treatment with low-dose acetylsalicylic
acid or low-dose acetylsalicylic acid and low-intensity
warfarin. The authors concluded that there were no dif-
ferences in thrombosis rate between both groups. Further-
more, warfarin was less safe and worse tolerated [165].
Secondary prevention of stroke in patients with aPL has
also been addressed in several studies. A study focusing on
arterial cerebral events showed similar rates of recurrent
thrombotic events over 2 years and risk of major bleeding
in patients treated with low-dose aspirin or warfarin ther-
apy [166]. Two prospective, randomized studies on APS
reported that treatment with high-intensity warfarin (INR
range 3–4) was not superior to moderate-intensity warfarin
(INR 2.0–3.0) in preventing recurrent thrombosis. The rate
of minor hemorrhagic complications was slightly increased
in patients treated with high-intensity anticoagulation [167,
168]. However, other authors have emphasized the limi-
tations of these trials and recommend the use of prolonged
warfarin therapy at a target INR[3.0 for all APS patients
with a first arterial thrombotic event [169]. The EULAR
recommendations for the management of NPSLE suggest
that anticoagulation may be superior to antiplatelet therapy
for secondary prevention of arterial events (including
stroke/TIA) in APS [38]. Furthermore, recent international
guidelines for the prevention and long-term management of
thrombosis in aPL-positive patients recommend the use of
warfarin therapy with a target INR [3.0, or an anti-ag-
gregant combined with anticoagulant therapy (INR
2.0–3.0) in patients with definite APS and arterial throm-
bosis. The lack of consensus over the optimal treatment in
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these cases exemplifies the debate generated on this topic
in the last few years, and stresses the need to start new
trials [38, 47, 162].
In SLE patients with cerebral venous and sinus throm-
bosis, treatment with oral anticoagulation is recommended.
The optimal duration of oral anticoagulant therapy after the
acute phase is unclear. Guidelines recommend oral anti-
coagulation (INR range 2.0–3.0) for 3–6 months, and in
patients with definite APS, long-term anticoagulation
should be considered [170].
Oral anticoagulation has also been used in NPSLE other
than cerebrovascular disease. In some SLE aPL-positive
patients with myelopathy, good functional outcomes have
been reported when added to immunosuppressive therapy
[38, 171]; however, other authors found no additional
benefit over standard immunosuppression alone and claim
that there is not enough evidence for anticoagulation in
these patients [172]. In SLE patients with chorea or seizure,
anticoagulation may be considered when associated with
aPL or when an ischemic subjacent process is suspected.
This therapy has also been successfully used in aPL-related
ischemic optic neuropathy and in SLE patients with posi-
tive aPL and cranial neuropathy not responding to
immunosuppressive therapy [38]. A single uncontrolled
study has suggested that APS patients with cognitive dys-
function may benefit from anticoagulation therapy [173].
6.5 Potential Future Therapies
6.5.1 Drugs in Development
Advances in the understanding of immunopathogenesis of
SLE have led to the development of immunotherapies
targeting B cells, T cells, the costimulatory modulation,
and cytokines. Pathogenic mechanisms in NPSLE are still
poorly understood. Furthermore, experimental models
using these new therapies are lacking; however, according
to what we already know about NPSLE pathogenesis, we
could speculate about the potential role of some of these
drugs in the future treatment of these manifestations.
The promising effect of rituximab may suggest an
important contribution of B cells to NPSLE pathogenesis.
Belimumab, a humanized monoclonal antibody targeted
against B lymphocyte stimulator (BLyS), is now licensed in
the US and Europe for the management of SLE. The BLISS
trials were neither designed nor powered to definitively
demonstrate the efficacy of belimumab in specific organ
systems. Other trials on therapies targeting BLyS, such as
tabalumab (phase II) and blisibimod (phase III) are ongoing.
Atacicept, a humanized fusion protein that binds BLyS and
APRIL (a proliferation-inducing ligand) has also been tested
in SLE patients [174]. Both BLyS and APRIL were shown
to be elevated in the CSF of SLE patients. Furthermore,
APRIL was increased in the CSF of NPSLE patients com-
pared with SLE patients without NP symptoms and other
neurological diseases. It has been suggested that BLyS and
APRIL are produced locally in the astrocytes of the brain
and that they may play a role in NPSLE etiology. Hence,
antagonists of these cytokines could have beneficial effect in
these patients [175, 176]. To date, results in SLE patients are
promising and further studies with these therapies are
awaited; however, patients with severe CNS manifestations
were excluded from all these trials, which will limit any
conclusion in this respect [177].
Epratuzumab, a humanized monoclonal antibody that
targets CD22 on B cells and results in modulation of B-cell
function and migration, has also been studied in SLE
patients. Although the EMBLEM and ALLEVIATE trials
showed promising results, the EMBODY I and EMBODY
II phase III clinical studies for epratuzumab in SLE did not
meet their primary clinical efficacy endpoints [178, 179].
Several drugs targeting cytokines that are thought to
contribute to the pathogenesis of both SLE and NPSLE are
currently being tested. For example, IFN-a is considered
one of the most promising therapeutic targets in SLE.
Sifalimumab, a human anti-IFN-a monoclonal antibody,
and rontalizumab, a humanized monoclonal antibody IgG1,
have shown promising results in reducing SLE disease
activity across multiple clinical measures [180]. Although
not confirmed in all studies, IFN-a is one of the inflam-
matory mediators related to NPSLE pathogenesis. Type I
IFNs are found in glia and neurons. Among their functions,
IFNs induce other inflammatory mediators such as IL-6,
alter brain neurotransmitters such as serotonin, and gen-
erate brain toxic metabolites. Subsequently, IFN-a has
been hypothesized as a potential target in NPSLE [181–
183].
A common characteristic of these new therapies is that
the impact on disease activity seems promising but must
still be assessed in phase III trials. Moreover, in most of
these trials, CNS involvement was an exclusion criterion,
and the potential to treat NPSLE will remain unknown
[177].
Several studies have confirmed the intrathecal presence
of higher levels of other cytokines in NPSLE. High levels
of tumor necrosis factor (TNF)-a, IL-6, and IFN-c are
found in CSF of NPSLE patients. The overproduction of
these cytokines is thought to play a role in the pathogenesis
and severity of NP symptoms, and they have been proposed
as candidate targets for future treatment [175, 184–186].
Two phase I trials with tocilizumab, an anti-IL-6 blocker,
and AMG 811, a monoclonal antibody against IFN-c, have
shown acceptable results and more studies are awaited
[187, 188].
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Although antibodies are administered intravenously and
may have a therapeutic effect on the brain, taking into
account the BBB disruption in NPSLE, these drugs may
require transport across the BBB using an endogenous
BBB peptide receptor transporter [189]. Ischemic NPSLE,
especially in the presence of aPL or APS, may benefit from
new-generation direct oral anticoagulants in the future,
including dabigatran etexilate, a direct thrombin inhibitor,
and rivaroxaban, apixaban and edoxaban, which are direct
anti-Xa inhibitors [190]. Although not currently recom-
mended in APS, these therapies may represent a potential
alternative for long-term anticoagulation in APS.
Rivaroxaban has shown good results in both arterial and
venous thrombosis; however, information is controversial
[191, 192]. More data will be drawn from ongoing studies.
6.5.2 Potential Future Targets
The BBB is a network of endothelial cells and pericyte and
astrocyte projections that regulates the entry of soluble
molecules and cells into the brain parenchyma. It has been
proposed that a disruption of the integrity of the BBB may
have a potential pathogenic role in NPSLE since this may
permit the influx of neuropathic antibodies across the BBB.
Many modulators of the integrity of the BBB have been
proposed. Among them, anti-endothelial cell antibodies,
complement components, cytokines and chemokines, and
environmental mediators have an essential role [193].
It has been speculated that ameliorating the disruption of
the BBB may have an important effect in the control of
NPSLE. Studies in MRL/lpr mice, accurately reflecting
human NPSLE, have shown the importance of TWEAK, a
pro-inflammatory cytokine member of the TNF superfam-
ily, and the alternative complement cascade in BBB
disruption.
TWEAK variably induces cellular proliferation, angio-
genesis, apoptosis, and the production of metallopro-
teinase, cytokines, and chemokines [194]. TWEAK has
been found to be increased in the cerebral cortices of MRL/
lpr mice. Furthermore, in a murine knockout model for its
receptor Fn14, mice were found to improve in cognitive
function and to have less depression and anhedonia [195].
Complement component C5 has been reported to play a
role in the maintenance of the BBB in mice [196]. Selec-
tive inhibition of C5aR alleviated CNS lupus [197]. Also,
inhibition of the classical and alternative complement
cascade with the complement inhibitor Crry was demon-
strated to alleviate experimental CNS lupus in mice [198].
Furthermore, complement plays a role in microvascular
injury. Mice deficient in C3 and C5 components are
resistant to enhanced thrombosis and endothelial cell
activation induced by aPL antibodies, indicating the
important role of alternative pathway complement activa-
tion on aPL antibody-mediated thrombogenesis [199, 200].
Based on this information, eculizumab, a humanized
monoclonal antibody blocking the generation of terminal
complement components C5a and C5b-9, may be a
potential drug to be used in the future in NPSLE [201].
7 Conclusions
NP symptoms constitute an uncommon and poorly under-
stood event in SLE patients, and pose a diagnostic and
therapeutic challenge to the physician. Management of
NPSLE patients has not evolved substantially in the last
decades and is characterized by the lack of good evidence
and the use of empirical therapies to date. It seems rea-
sonable that increased understanding of the pathogenesis of
NPSLE and any of its manifestations will promote the
possibility of finding targeted therapies and an evidence-
based approach to management.
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